Haemonetics Corporation (HAE)vsEli Lilly and Company (LLY)
HAE
Haemonetics Corporation
$71.28
+2.05%
HEALTHCARE · Cap: $3.55B
LLY
Eli Lilly and Company
$1,131.42
-1.21%
HEALTHCARE · Cap: $1.01T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 5316% more annual revenue ($72.25B vs $1.33B). LLY leads profitability with a 35.0% profit margin vs 7.3%. HAE appears more attractively valued with a PEG of 1.25. LLY earns a higher WallStSmart Score of 76/100 (B+).
HAE
Buy56
out of 100
Grade: C
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+33.9%
Fair Value
$86.95
Current Price
$71.28
$15.67 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 28.4% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Premium valuation, high expectations priced in
4.8% revenue growth
Distress zone — elevated risk
7.3% margin — thin
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : HAE
The strongest argument for HAE centers on EPS Growth. PEG of 1.25 suggests the stock is reasonably priced for its growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : HAE
The primary concerns for HAE are P/E Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 1.54 is elevated, increasing financial risk.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Key Dynamics to Monitor
HAE profiles as a value stock while LLY is a growth play — different risk/reward profiles.
HAE carries more volatility with a beta of 0.54 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 56/100), backed by strong 35.0% margins and 55.5% revenue growth. HAE offers better value entry with a 33.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?